JP2024014991A - Agent for preventing and/or treating acne on back - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide an agent that can treat acne on the back, has compatibility with sebum, inhibits the proliferation of bacteria responsible for acne on the back, and also offers superior usability.

SOLUTION: A agent for preventing and/or treating acne on the back includes (A) at least one selected from the group consisting of salicylic acid and salts thereof, isopropylmethylphenol, sulfur, resorcin, ibuprofen piconol, dipotassium glycyrrhizinate, glycyrrhetinic acid, allantoin, zinc oxide, diphenhydramine, homosulfamine, sulfadiazine, and tocopheryl acetate and (B) ethanol of less than 22.84 wt.%.

SELECTED DRAWING: None

COPYRIGHT: (C)2024,JPO&INPIT

Description

The present invention relates to a drug for preventing and/or treating acne on the back.

Acne is caused by increased secretion of sebum in the hair follicles and blockage by sebum and dead skin cells, and by Prop. acnes.
It is an inflammatory skin disease caused by a variety of causes, including proliferation of fungi such as Nibacterium acnes, Staphylococcus aureus, and Malassezia fungi. Acne can occur in various areas such as the face, back, chest, upper arms, neck, etc. due to the influence of excessive sweat, high temperature, high humidity, clothing, etc., but the number and type of bacteria that cause it differ depending on the area where it occurs. It has become clear that this is the case (Non-Patent Document 1).

It has been reported that fungi of the genus Malassezia are involved in acne on the back (Non-Patent Document 2).
, Malassezia fungi include M. furfur, M. globosa, M. restr
Several species such as icta are known.

Written by Yoshihiro Kiyo, Jpn. J. Med. Mycol. , Vol. 47 (No. 2), 2006 Written by Yoshihiro Kiyo, Visual Dermatology, Vol. 9 (No. 11), 2010

However, no drug has been reported that is particularly effective against acne on the back.

The present invention has been made in view of the above, and aims to provide a drug that is compatible with sebum, inhibits the growth of acne-causing bacteria on the back, and has an excellent feeling of use.

In view of the above issues, as a result of intensive studies, we have sufficiently lowered the ethanol concentration and added salicylic acid and its salts, isopropylmethylphenol (IPMP), sulfur, resorcinol, ibuprofen piconol, dipotassium glycyrrhizinate, and glycyrrhetinic acid as active ingredients. , allantoin, zinc oxide, diphenhydramine, homosulfamine, sulfadiazine, and tocopherol acetate, the use of at least one selected from the group consisting of: The present invention has now been completed.

That is, the present invention provides the following drugs for preventing and/or treating acne on the back.
Item 1.
(A) selected from the group consisting of salicylic acid and its salts, isopropylmethylphenol, sulfur, resorcinol, ibuprofenpiconol, dipotassium glycyrrhizinate, glycyrrhetinic acid, allantoin, zinc oxide, diphenhydramine, homosulfamine, sulfadiazine, and tocopherol acetate; at least one species, and
(B) A drug for preventing and/or treating acne for the back, containing less than 22.84% by weight of ethanol.
Item 2.
Item 1. The drug for preventing and/or treating acne on the back according to item 1, wherein the total content of the component (A) is 0.0001% to 30% by weight.
Item 3.
Item 2. The drug for preventing and/or treating acne for back according to item 1 or 2, which is housed in a spray type container.
Item 4.
Item 3. The drug for preventing and/or treating acne on the back according to any one of Items 1 to 3, further comprising 1,3-butylene glycol and/or glycerin.
Item 5.
Item 4. The drug for preventing and/or treating acne on the back according to any one of Items 1 to 4, which has a pH of 2.5 to 5.5.

The present invention also provides the following composition for external use.
Item 6.
(A) selected from the group consisting of salicylic acid and its salts, isopropylmethylphenol, sulfur, resorcinol, ibuprofenpiconol, dipotassium glycyrrhizinate, glycyrrhetinic acid, allantoin, zinc oxide, diphenhydramine, homosulfamine, sulfadiazine, and tocopherol acetate; at least one species, and
(B) An external composition for inhibiting the growth of Malassezia fungi on the back, containing less than 22.84% by weight of ethanol.
In another aspect, it is possible to provide the composition for external use according to Item 6, wherein the total content of the component (A) is 0.0001% to 30% by weight.
In another embodiment, the external composition according to item 6 can be provided, which is housed in a spray type container.
In another embodiment, the external composition according to item 6, further containing 1,3-butylene glycol and/or glycerin, can be provided.
In another embodiment, the external composition according to item 6, having a pH of 2.5 to 5.5, can be provided.

According to the present invention, it is possible to provide a drug for preventing and/or treating acne on the back that can effectively suppress bacteria that cause acne on the back and that causes less unpleasant sensations such as irritation.

FIG. 3 is a diagram showing the results of evaluating the compatibility with sebum in a composition containing less than 22.84% by weight of ethanol in Test Example 1-1. FIG. 2 is a diagram showing the results of evaluating the compatibility with sebum in a composition containing salicylic acid as component (A) and containing less than 22.84% by weight of ethanol in Test Example 1-2. FIG. 3 is a diagram showing the results of evaluating the compatibility with sebum in a composition containing salicylic acid as component (A) and containing less than 22.84% by weight of ethanol in Test Example 1-3. FIG. 4 is a diagram showing the results of evaluating the compatibility with sebum in a composition containing isopropylmethylphenol as component (A) and containing less than 22.84% by weight of ethanol in Test Example 1-4. FIG. 4 is a diagram showing the results of evaluating the compatibility with sebum in a composition containing ibuprofen piconol as component (A) and containing less than 22.84% by weight of ethanol in Test Example 1-5. FIG. 6 is a diagram showing the results of evaluating the compatibility with sebum in a composition containing allantoin as component (A) and containing less than 22.84% by weight of ethanol in Test Example 1-6. FIG. 7 is a diagram showing the results of evaluating the compatibility with sebum in a composition containing glycyrrhetinic acid as the component (A) and containing less than 22.84% by weight of ethanol in Test Example 1-7. FIG. 7 is a diagram showing the results of evaluating the compatibility with sebum in a composition containing sulfur as the component (A) and containing less than 22.84% by weight of ethanol in Test Example 1-8. FIG. 9 is a diagram showing the results of evaluating the compatibility with sebum in a composition containing resorcinin as component (A) and containing less than 22.84% by weight of ethanol in Test Example 1-9. FIG. 3 is a diagram showing the results of evaluating the compatibility with sebum in a composition containing tocopherol acetate as component (A) and containing less than 22.84% by weight of ethanol in Test Example 1-10. In Test Example 1-11, sebum in a composition containing salicylic acid, allantoin, and sulfur as components (A), POE (9) lauryl ether as a surfactant, and less than 22.84% by weight of ethanol. It is a figure which shows the result of evaluating the familiarity to. FIG. 3 is a diagram showing the results of evaluating the growth inhibitory effect on three types of Malassezia fungi in Test Example 2. In Test Example 3-1, the results of a sensory test regarding the evaluation item of "stimulation (tingling sensation)" in a composition containing salicylic acid as the component (A) and containing less than 22.84% by weight of ethanol. FIG. FIG. 3 is a diagram showing the results of a sensory test regarding the evaluation item of "hot flashes" in a composition containing salicylic acid as component (A) and less than 22.84% by weight of ethanol in Test Example 3-1. FIG. 3 is a diagram showing the results of a sensory test regarding the evaluation item of “tightness” in a composition containing salicylic acid as component (A) and less than 22.84% by weight of ethanol in Test Example 3-1. FIG. 3 is a diagram showing the results of a sensory test regarding the evaluation item of “itchiness” in a composition containing salicylic acid as component (A) and less than 22.84% by weight of ethanol in Test Example 3-1. FIG. 3 is a diagram showing the results of a sensory test regarding the evaluation item of "unnatural feeling" in a composition containing salicylic acid as component (A) and less than 22.84% by weight of ethanol in Test Example 3-1. In Test Example 3-2, the results of a sensory test regarding the evaluation item of "stimulation (tingling sensation)" in a composition containing allantoin as the component (A) and containing less than 22.84% by weight of ethanol. FIG. FIG. 3 is a diagram showing the results of a sensory test regarding the evaluation item of "hot flashes" in a composition containing allantoin as component (A) and less than 22.84% by weight of ethanol in Test Example 3-2. FIG. 3 is a diagram showing the results of a sensory test regarding the evaluation item of “tightness” in a composition containing allantoin as component (A) and less than 22.84% by weight of ethanol in Test Example 3-2. FIG. 3 is a diagram showing the results of a sensory test regarding the evaluation item of “itchiness” in a composition containing allantoin as component (A) and less than 22.84% by weight of ethanol in Test Example 3-2. FIG. 3 is a diagram showing the results of a sensory test regarding the evaluation item of “unnatural feeling” in a composition containing allantoin as component (A) and less than 22.84% by weight of ethanol in Test Example 3-2. In Test Example 3-3, a sensory test was conducted on the evaluation item of "stimulation (tingling sensation)" in a composition containing ibuprofen piconol as the component (A) and containing less than 22.84% by weight of ethanol. It is a figure showing a result. In Test Example 3-3, this figure shows the results of a sensory test regarding the evaluation item of "hot flashes" in a composition containing ibuprofen piconol as the component (A) and containing less than 22.84% ethanol by weight. be. In Test Example 3-3, this is a diagram showing the results of a sensory test regarding the evaluation item of "tightness" in a composition containing ibuprofen piconol as the component (A) and containing less than 22.84% ethanol by weight. be. In Test Example 3-3, this figure shows the results of a sensory test regarding the evaluation item of "itchiness" in a composition containing ibuprofen piconol as the component (A) and containing less than 22.84% ethanol by weight. be. In Test Example 3-3, this figure shows the results of a sensory test regarding the evaluation item of "uncomfortable feeling" in a composition containing ibuprofen piconol as component (A) and containing less than 22.84% ethanol by weight. be. In Test Example 3-4, a sensory test was conducted on the evaluation item of "stimulation (tingling sensation)" in a composition containing isopropylmethylphenol as component (A) and ethanol less than 22.84% by weight. It is a figure showing a result. In Test Example 3-4, this figure shows the results of a sensory test regarding the evaluation item of "hot flashes" in a composition containing isopropylmethylphenol as component (A) and containing less than 22.84% ethanol by weight. be. In Test Example 3-4, this is a diagram showing the results of a sensory test regarding the evaluation item of "tightness" in a composition containing isopropylmethylphenol as component (A) and containing less than 22.84% ethanol by weight. be. In Test Example 3-4, this figure shows the results of a sensory test regarding the evaluation item of "itchiness" in a composition containing isopropylmethylphenol as component (A) and containing less than 22.84% ethanol by weight. be. In Test Example 3-4, this figure shows the results of a sensory test regarding the evaluation item of "unnatural feeling" in a composition containing isopropylmethylphenol as component (A) and containing less than 22.84% by weight of ethanol. be. In Test Example 3-5, the results of a sensory test regarding the evaluation item of "stimulation (tingling sensation)" in a composition containing sulfur as the component (A) and containing less than 22.84% ethanol by weight are as follows: FIG. FIG. 3 is a diagram showing the results of a sensory test regarding the evaluation item of "hot flashes" in a composition containing sulfur as component (A) and less than 22.84% by weight of ethanol in Test Example 3-5. FIG. 3 is a diagram showing the results of a sensory test regarding the evaluation item of "tightness" in a composition containing sulfur as component (A) and less than 22.84% by weight of ethanol in Test Example 3-5. FIG. 4 is a diagram showing the results of a sensory test regarding the evaluation item of "itchiness" in a composition containing sulfur as component (A) and less than 22.84% by weight of ethanol in Test Example 3-5. FIG. 3 is a diagram showing the results of a sensory test regarding the evaluation item of “unnatural feeling” in a composition containing sulfur as component (A) and less than 22.84% by weight of ethanol in Test Example 3-5. In Test Example 3-6, the results of a sensory test regarding the evaluation item of "stimulation (tingling sensation)" in a composition containing resorcinol as the component (A) and containing less than 22.84% by weight of ethanol are as follows: FIG. In Test Example 3-6, it is a diagram showing the results of a sensory test regarding the evaluation item of "hot flashes" in a composition containing resorcinin as the component (A) and containing less than 22.84% by weight of ethanol. FIG. 3 is a diagram showing the results of a sensory test regarding the evaluation item of “tightness” in a composition containing resorcinol as component (A) and less than 22.84% by weight of ethanol in Test Example 3-6. FIG. 4 is a diagram showing the results of a sensory test regarding the evaluation item of "itchiness" in a composition containing resorcinin as component (A) and containing less than 22.84% by weight of ethanol in Test Example 3-6. FIG. 4 is a diagram showing the results of a sensory test regarding the evaluation item of "uncomfortable feeling" in a composition containing resorcinin as component (A) and containing less than 22.84% by weight of ethanol in Test Example 3-6. In Test Example 3-7, a composition containing salicylic acid as the component (A), POE(9) lauryl ether as a surfactant, and less than 22.84% ethanol by weight caused a "stimulating feeling" FIG. 3 is a diagram showing the results of a sensory test regarding the evaluation item "Feeling". In Test Example 3-7, evaluation of "hot flashes" in a composition containing salicylic acid as component (A), POE (9) lauryl ether as a surfactant, and less than 22.84% by weight of ethanol. FIG. 3 is a diagram showing the results of a sensory test regarding the items. In Test Example 3-7, evaluation of "tightness" in a composition containing salicylic acid as component (A), POE (9) lauryl ether as a surfactant, and less than 22.84% by weight of ethanol. FIG. 3 is a diagram showing the results of a sensory test regarding the items. In Test Example 3-7, evaluation of "itchiness" in a composition containing salicylic acid as component (A), POE (9) lauryl ether as a surfactant, and less than 22.84% by weight of ethanol. FIG. 3 is a diagram showing the results of a sensory test regarding the items. In Test Example 3-7, evaluation of "unnatural feeling" in a composition containing salicylic acid as component (A), POE (9) lauryl ether as a surfactant, and less than 22.84% by weight of ethanol. FIG. 3 is a diagram showing the results of a sensory test regarding the items. In Test Example 3-8, the evaluation item of "Irritating feeling (tingling feeling)" in a composition containing allantoin as component (A), no surfactant, and less than 22.84% by weight of ethanol FIG. 2 is a diagram showing the results of a sensory test for In Test Example 3-8, a sensory test was conducted on the evaluation item of "hot flashes" in a composition containing allantoin as component (A), no surfactant, and less than 22.84% by weight of ethanol. FIG. In Test Example 3-8, a sensory test was conducted on the evaluation item of "tightness" in a composition containing allantoin as component (A), no surfactant, and less than 22.84% by weight of ethanol. FIG. In Test Example 3-8, a sensory test was conducted on the evaluation item of "itchiness" in a composition containing allantoin as component (A), no surfactant, and less than 22.84% by weight of ethanol. FIG. In Test Example 3-8, a sensory test was conducted on the evaluation item of "unnatural feeling" in a composition containing allantoin as component (A), no surfactant, and less than 22.84% by weight of ethanol. FIG.

[Back acne prevention and/or treatment drug]
The drug for preventing and/or treating acne for the back of the present invention includes:
(A) selected from the group consisting of salicylic acid and its salts, isopropylmethylphenol, sulfur, resorcinol, ibuprofenpiconol, dipotassium glycyrrhizinate, glycyrrhetinic acid, allantoin, zinc oxide, diphenhydramine, homosulfamine, sulfadiazine, and tocopherol acetate; at least one species, and
(B) Contains less than 22.84% by weight of ethanol.

[(A) Component]
Among the components (A), known substances can be used as salicylic acid and its salts,
There are no particular restrictions. Salts of salicylic acid are not particularly limited as long as they are medicinally, pharmacologically (pharmacologically) or physiologically acceptable, and include, for example, alkali metal salts, alkaline earth metal salts,
Examples include salts with organic bases and the like. Examples of the salicylate include at least one selected from the group consisting of sodium salicylate, calcium salicylate, magnesium salicylate, and potassium salicylate. (A) Salicylic acid and its salts are preferably at least one selected from the group consisting of salicylic acid, sodium salicylate, calcium salicylate, magnesium salicylate, and potassium salicylate, from the viewpoint of significantly exhibiting the effects of the present invention, and salicylic acid and/or Sodium salicylate is more preferred. (A) Salicylic acid and its salts may be synthesized and used, or commercially available products may be used. In another aspect, (A
) It is also possible to use a derivative of salicylic acid as the component. Such derivatives of salicylic acid are not particularly limited as long as they are known substances that can be used for the prevention and/or treatment of acne. Contains propylene glycol, Ti salicylate, etc.

Among the components (A), isopropylmethylphenol is a substance known as a nonionic antibacterial agent, and may be synthesized and used, or a commercially available product may be used.

Among component (A), sulfur is a substance known as an antibacterial agent, and may be collected and extracted from nature, or may be obtained by chemical methods. When obtained from nature, sulfur can be collected and extracted from natural sulfur deposits, for example. When obtained by a chemical method, sulfur can be obtained from, for example, sulfur content such as liquid sulfur extracted during the process of refining crude oil. When using a commercially available product, for example, sulfur (manufactured by Matsumoto Kosho Co., Ltd.) can be used.

Among the components (A), resorcinol, also called resorcinol, is a substance known as a bactericidal agent, and may be synthesized and used, or a commercially available product may be used.

Among components (A), ibuprofen piconol, dipotassium glycyrrhizinate, glycyrrhetinic acid, and allantoin are substances known as anti-inflammatory ingredients, and may be synthesized and used, or commercially available products may be used.

Among the components (A), zinc oxide is a substance known as an astringent/protective component, and may be synthesized and used, or a commercially available product may be used.

Among the components (A), diphenhydramine is a substance known as an antihistamine,
It may be synthesized and used, or a commercially available product may be used.

Among component (A), homosulfamine and sulfadiazine are substances known as bactericidal agents, and may be synthesized and used, or commercially available products may be used.

Among the components (A), tocopherol acetate (vitamin E) is a substance known as a blood circulation improving component, and may be synthesized and used, or a commercially available product may be used.

All of these components (A) may be used alone or in any combination of two or more. Although not limited, from the viewpoint of significantly achieving the effects of the present invention, component (A) is a group consisting of salicylic acid and its salts, isopropylmethylphenol, sulfur, resorcinol, ibuprofen piconol, glycyrrhetinic acid, tocopherol acetate, and allantoin. At least one selected from these is preferred. Moreover, from the viewpoint of achieving more remarkable effects of the present invention, it is preferable to combine two or more types of component (A). When combining two or more types of components (A), there is no limitation, and the combination is appropriately set depending on the types and contents of other ingredients, formulation form, usage method, etc. Although not limited, preferred combinations of two or more types of component (A) are illustrated in Table 1 below.

Although the combination of these components (A) is not limited, a combination of salicylic acid and its salt, isopropylmethylphenol, and allantoin is more preferable from the viewpoint of significantly exhibiting the effects of the present invention.

In the back acne prevention and/or treatment drug of the present invention, the content of component (A) is (A)
It is determined as appropriate depending on the type of ingredient, the type and content of other ingredients, formulation form, usage method, etc., but the amount of ingredient (A) is determined based on the total amount of the back acne prevention and/or treatment drug. The total content is preferably 0.0001% by weight or more, more preferably 0.001% by weight or more,
The content is more preferably 0.005% by weight or more, particularly preferably 0.01% by weight or more, and most preferably 0.2% by weight or more. Furthermore, the total content of component (A) is preferably 30% by weight or less, more preferably 20% by weight or less, based on the total amount of the drug for preventing and/or treating acne for the back.
The amount is not more than 10% by weight, more preferably not more than 10% by weight, particularly preferably not more than 5% by weight, and most preferably not more than 3% by weight. For the total amount of the back acne prevention and/or treatment drug, (A
) The total content of the components is preferably 0.0001% to 30% by weight, more preferably 0.001% to 20% by weight, even more preferably 0.005% to 10% by weight, particularly preferably is from 0.01% to 5% by weight, most preferably from 0.2% to 3% by weight.

Although not limited, in a preferred embodiment, for example, when salicylic acid and its salt is contained as the component (A), for example, the sole content of salicylic acid and its salt is the same as that of the back acne prevention and/or treatment drug. Based on the total amount, it is preferably 0.0001% to 5% by weight, more preferably 0.0005% to 3% by weight, and 0.001% to 1% by weight.
It is more preferably 0.01% to 0.5% by weight, particularly preferably 0.5% by weight.

In a preferred embodiment, for example, but not limited to, isopropylmethylphenol (A
) When it is contained as a component, for example, the content of isopropylmethylphenol alone is 0.0001% to 5% by weight based on the total amount of the drug for preventing and/or treating acne on the back.
It is preferably 0.0005% to 3% by weight, more preferably 0.0005% to 3% by weight.
It is more preferably from 0.01% to 1% by weight, even more preferably from 0.01% to 0.3% by weight, and particularly preferably from 0.3% by weight.

Although not limited, in a preferred embodiment, for example, when sulfur is contained as component (A), the content of sulfur alone is 0 with respect to the total amount of the back acne prevention and/or treatment drug. The content is preferably from .0001% to 10% by weight, more preferably from 0.0005% to 8% by weight, even more preferably from 0.001% to 5% by weight, and even more preferably from 0.01% by weight. % to 3% by weight is even more preferable, and 3% by weight is particularly preferable.

Although not limited, in a preferred embodiment, for example, when resorcin is contained as component (A), the content of resorcin alone is 0 with respect to the total amount of the back acne preventive and/or therapeutic agent. It is preferably 0.0001% to 10% by weight, and 0.0005% by weight.
It is more preferably from 0.001% to 5% by weight, even more preferably from 0.01% to 2% by weight, and even more preferably from 2% by weight. It is particularly preferable to do so.

Although not limited, in a preferred embodiment, for example, when ibuprofen piconol is contained as component (A), the content of ibuprofen piconol alone is less than the total amount of the back acne preventive and/or therapeutic agent. In contrast, it is preferably 0.0001% to 10% by weight, more preferably 0.0005% to 7% by weight, and 0.001% by weight to 7% by weight.
It is more preferably from 0.01% to 3% by weight, even more preferably from 0.01% to 3% by weight, and particularly preferably from 3% by weight.

Although not limited to, in a preferred embodiment, for example, dipotassium glycyrrhizinate (A)
When contained as a component, for example, the content of dipotassium glycyrrhizinate alone is preferably 0.0001% by weight to 10% by weight based on the total amount of the drug for preventing and/or treating acne on the back. , more preferably 0.0005% to 7% by weight, and 0.0% by weight.
It is more preferably 0.01% to 5% by weight, even more preferably 0.01% to 0.5% by weight, and particularly preferably 0.5% by weight.

Although not limited, in a preferred embodiment, for example, when glycyrrhetinic acid is contained as component (A), the content of glycyrrhetinic acid alone is based on the total amount of the back acne preventive and/or therapeutic agent. , preferably from 0.0001% to 10% by weight,
More preferably 0.0005% to 7% by weight, 0.001% to 5% by weight
It is more preferably 0.01% by weight to 0.3% by weight, even more preferably 0.3% by weight.

Although not limited, in a preferred embodiment, for example, when allantoin is contained as component (A), the content of allantoin alone is 0 with respect to the total amount of the back acne preventive and/or therapeutic agent. The content is preferably 0.0001% to 5% by weight, and 0.000% by weight.
It is more preferably 5% to 3% by weight, even more preferably 0.001% to 1% by weight, even more preferably 0.01% to 0.5% by weight, and even more preferably 0.01% to 1% by weight. .0
It is particularly preferable to set the amount to 1% by weight to 0.2% by weight.

Although not limited, in a preferred embodiment, for example, when zinc oxide is contained as component (A), the content of zinc oxide alone is less than the total amount of the back acne preventive and/or therapeutic agent. , preferably 0.0001% to 10% by weight, more preferably 0.0005% to 7% by weight, even more preferably 0.001% to 5% by weight, and even more preferably 0.0001% to 10% by weight. It is even more preferable to set the amount to 01% to 2% by weight, and particularly preferably to set it to 2% by weight.

Although not limited, in a preferred embodiment, for example, when diphenhydramine is contained as component (A), the content of diphenhydramine alone is 0 with respect to the total amount of the back acne preventive and/or therapeutic agent. The amount is preferably .0001% to 5% by weight, more preferably 0.0005% to 3% by weight, even more preferably 0.001% to 1% by weight, and 0.01% by weight. % to 0.5% by weight is even more preferable, and 0.5% by weight is particularly preferable.

Although not limited, in a preferred embodiment, for example, when homosulfamine is contained as component (A), the content of homosulfamine alone is based on the total amount of the back acne preventive and/or therapeutic agent. , preferably from 0.0001% to 10% by weight,
More preferably 0.0005% to 7% by weight, 0.001% to 5% by weight
It is more preferably 0.01% by weight to 0.3% by weight, even more preferably 0.3% by weight.

Although not limited, in a preferred embodiment, for example, when sulfadiazine is contained as component (A), the content of sulfadiazine alone is 0 with respect to the total amount of the back acne preventive and/or therapeutic agent. Preferably, the content is from .0001% by weight to 10% by weight,
More preferably 0.0005% to 7% by weight, 0.001% to 5% by weight
It is more preferable to set the content to 5% by weight, particularly preferably 5% by weight.

Although not limited, in a preferred embodiment, for example, tocopherol acetate (A)
When contained as a component, for example, the content of tocopherol acetate alone is preferably 0.0001% to 5% by weight based on the total amount of the drug for preventing and/or treating acne on the back. More preferably 0.0005% to 3% by weight, 0.00% by weight
It is more preferably 1% to 1% by weight, even more preferably 0.01% to 0.5% by weight, and particularly preferably 0.5% by weight.

[(B) Component]
The drug for preventing and/or treating acne for the back of the present invention contains 0% or more by weight of ethanol22.
Contains less than 84% by weight. The present invention provides a drug for preventing and/or treating acne for the back containing the component (A) by reducing the content of ethanol to less than 22.84% by weight or by not containing ethanol. It is particularly effective in preventing and/or treating acne.

Ethanol is not particularly limited as long as it is of a grade used in pharmaceuticals, quasi-drugs, cosmetics, etc. As the ethanol, for example, 95% ethanol, 99% ethanol (anhydrous ethanol), etc. can be used as appropriate.

In the back acne prevention and/or treatment drug of the present invention, the content of ethanol is appropriately set depending on the type and content of other ingredients, formulation form, usage method, etc. / Or with respect to the total amount of the therapeutic agent, the content of ethanol can be 0% by weight or more, 0.00001% by weight or more, 0.001% by weight or more, 0.01% by weight or more, 0
．． It can also be 1% by weight or more, 1% by weight or more, 2% by weight or more, or 3% by weight or more. Moreover, the content of ethanol is 22.0% with respect to the total amount of the drug for preventing and/or treating acne on the back.
It can be less than 84% by weight, 21% by weight or less, 20% by weight or less, 15% by weight or less,
It can also be 14% by weight or less, 12% by weight or less, 9% by weight or less, or 3% by weight or less. In addition, the content of ethanol can be 0% by weight or more and less than 22.84% by weight, preferably 0% to 21% by weight, based on the total amount of the drug for preventing and/or treating acne for the back. More preferably 0% to 20% by weight, even more preferably 0% to 15% by weight, even more preferably 0.00001% to 15% by weight, even more preferably 0.01% to 15% by weight.
% by weight, even more preferably from 1% to 14%, even more preferably from 1% to 9%, even more preferably from 2% to 9%, particularly preferably from 3% to 9%. be.

In the back acne preventive and/or therapeutic agent of the present invention, from the viewpoint of achieving the effects of the present invention more markedly, the blending ratio of component (B) to component (A) is determined by, for example, the total content of component (A). The total content of component (B) can be 0 to 500 parts by weight per 1 part by weight,
0-300 parts by weight, 0-250 parts by weight, 0-200 parts by weight, 0-150 parts by weight, 0-10
0 parts by weight, 0 to 50 parts by weight, 0 to 30 parts by weight, 0 to 20 parts by weight, 0 to 17 parts by weight, 0 to 1
0 parts by weight, 0 to 5 parts by weight, 0 to 3 parts by weight, 0 to 0.7 parts by weight, 0 to 0.1 parts by weight, 0.0
It is also possible to set the amount to 1 to 2 parts by weight, or 0.1 to 1 part by weight.

[Application]
The present invention is used in the treatment of acne on the back. The causes of acne on the back include increased secretion of sebum in the hair follicles, blockage by sebum and dead skin cells, and Propionibacterium ac
nes), the proliferation of Staphylococcus aureus, fungi of the Malassezia genus, etc., and these may occur in combination. In this specification, "acne on the back" is not limited as long as acne occurs on the back. "Acne on the back" is (
Not limited to acne (common acne), the affected area can be recognized as a skin eruption, rash, or papule that is red, crimson, brown, white, or the same color as the skin, depending on the causative bacteria. In the general consumer's understanding, "back acne" is sometimes referred to as bumps, pimples, boils, etc. that occur on the back. The distribution of affected areas may be widespread on the back, localized in one area, or scattered.

In particular, the back, unlike the face, neck, arms, etc., does not have an open area when wearing clothes, so it is prone to sweaty, hot, and humid environments. Furthermore, since the back is constantly in contact with clothing, it is also an environment where it is susceptible to physical stimulation. In addition, the back of the chair is compressed and irritated by the backrest of the chair, making it difficult for ventilation and air circulation to occur. In such an environment, among the bacteria that cause acne on the back, fungi of the genus Malassezia, which prefer high temperature and humid environments, tend to grow. Furthermore, it is known that P. acnes is the main causative bacteria for acne on the face, and the types and proportions of causative bacteria are different from acne on the back.

As a fungus of the genus Malassezia, M. globosa, M. restricta, M. fu
rfur, M. dermatis, M. slooffiae, M. sympodiali
s, M. japonica, M. yamatoensis, M. obtusa, M. na
na, M. pachydermatis, M. equina, M. caprae et al. These Malassezia fungi have been reported to be involved in various skin diseases, including tinea versicolor, Malassezia folliculitis, seborrheic eczema (also called seborrheic dermatitis), seborrheic keratosis, and atopic dermatitis. It is known as a cause or aggravating factor of sexual dermatitis, otitis externa, etc.

The drug for preventing and/or treating back acne of the present invention can be effectively used against various acne-causing bacteria, but is preferably used against various acne-causing bacteria. restricta, M. globosa and M. globosa. It is used to suppress the proliferation of at least one species selected from the group consisting of M. furfur, and among them, M. furfur. furfur and M. It is advantageously used to suppress the proliferation of M. globosa, more preferably M. globosa. restricta, M. globosa, and M. globosa. f
It is used to suppress the proliferation of urfur.

M. Globosa predominates in Malassezia folliculitis that tends to occur on the back, is involved in aggravation of the lesion, and is known to be relatively predominant compared to other fungi of the genus Malassezia. M. It is known that among fungi of the genus Malassezia, S. globosa has particularly high lipase activity and tends to promote sebum decomposition and generate free fatty acids that induce skin irritation. Also, M. Among fungi of the genus Malassezia resident on the skin, P. restricta is frequently detected in Malassezia folliculitis, and has high lipase activity. M. fu
Although rfur has a lower lipase activity than the above two types, it is known to easily induce inflammatory cytokines and may have a high inflammatory effect due to immune reactions. The drug for preventing and/or treating back acne of the present invention is particularly effective in suppressing the proliferation of these fungi of the genus Malassezia, and therefore can effectively treat diseases or symptoms associated with the proliferation of these fungi of the genus Malassezia. It can be treated, ameliorated, or prevented.

[pH]
The pH of the drug for preventing and/or treating back acne of the present invention is appropriately set depending on the type of component (A), the type and content of other ingredients, the formulation form, the method of use, etc. The pH is not limited as long as it is within an acceptable range; for example, the pH may be 2 to 9. From the viewpoint of stably exhibiting the effects of the present invention, the pH of the drug for preventing and/or treating back acne of the present invention is preferably 2 to 8, more preferably 2 to 7, still more preferably 2 to 6, and even more preferably 2 to 7. More preferably from 2.5 to 5.5, even more preferably from 2.6 to 5, even more preferably from 2.6 to 5.
4.8, and even more preferably 2.6 to 4.5.

[Dosage form]
The drug for preventing and/or treating acne for the back of the present invention is not particularly limited as long as it is in a form known as a pharmaceutical, quasi-drug, or cosmetic, but examples include a solution, a suspension, an emulsion, a cream,
It is formulated by a known method in the form of an ointment, a gel, a liniment, a lotion, an aerosol, a powder, a sheet of nonwoven fabric, etc. impregnated with a back acne prevention and/or treatment drug. be able to.

If the drug for preventing and/or treating back acne is formulated in a liquid form such as a solution, suspension, emulsion, cream, gel, lotion, etc., it may be stored in a spray-type container, but is not limited to this. This is preferable because the drug for preventing and/or treating back acne of the present invention can be directly sprayed onto the affected area. After spraying, it can also be spread and spread using a nonwoven cloth, fingers, or the like. When a back acne prevention and/or treatment drug is formulated in a liquid or semi-solid form in the form of a solution, suspension, emulsion, cream, ointment, gel, lotion, etc., the nozzle may be used without limitation. By storing the drug in a container with an attached container, the drug for preventing and/or treating back acne of the present invention can be directly applied to the affected area. By using a rotating body such as a roll or a ball at the tip of the nozzle, it is also possible to design the nozzle so that the anti-acne preventive and/or therapeutic agent of the present invention is evenly applied to the affected area. After applying the drug for preventing and/or treating back acne of the present invention to the affected area, it can also be used by spreading it with a non-woven fabric, fingers, or the like.

When applying the drug for preventing and/or treating back acne of the present invention to the back, it is preferable to use a spray type container so that it can be easily applied to affected areas that are difficult to reach. The spray type container is more preferably a mist type spray type container that can spray even if it is turned upside down. The shape of the spray type container is not particularly limited, but for example, known shapes such as a pump type spray, a trigger type spray, an aerosol type spray, etc. can be used. In the case of a pump-type spray, for example, a pump-type nozzle can be attached to a container, and is excellent in versatility and portability. In a trigger-type spray, for example, a pistol-type atomizer with a nozzle can be attached to a container, and spray power can be obtained with a small amount of force. In an aerosol spray, a container filled with a propellant such as carbon dioxide gas, nitrogen gas, oxygen gas, or chlorofluorocarbon gas can be used, and finer droplets can be sprayed. The material of the spray type container is not particularly limited, but for example, known plastic materials such as polypropylene and polyethylene can be used.

The pump-type dispenser and trigger-type dispenser are dispensers that have a function of discharging mist (fog), and are not particularly limited as long as they are commonly available. The amount to be discharged in one discharge process is not particularly limited as long as the effect of the present invention is sufficiently exhibited, but from the viewpoint of uniform application to the desired area of the back, it is 0.05 to 1.5 mL.
The amount is preferably in the range of 0.5 to 1 mL/time, more preferably 0.5 to 1 mL/time. As a container to be filled with the drug for preventing and/or treating back acne of the present invention, a commercially available container can be used. For example, as a pump type dispenser, Yoshino Kogyo Co., Ltd.
-150 (discharges approximately 0.15 mL per push), Z-155 manufactured by Mitani Valve Co., Ltd. (discharges approximately 0.15 mL per push); As a trigger type dispenser, M3-M manufactured by Yoshino Kogyo Co., Ltd.
Discharge approximately 0.5 mL at a time), Z-305, T-305 manufactured by Mitani Valve Co., Ltd. (discharge approximately 0.3 mL at a time)
emissions), etc.

The method of using the drug for preventing and/or treating back acne of the present invention may be changed as appropriate depending on the condition of back acne, age, gender, etc. of the subject using the drug.
It can be used by applying an appropriate amount to the skin of the back about 1 to 5 times, preferably 2 to 3 times, and it is best to apply an appropriate amount to the affected area twice a day (morning and evening). preferable. The application period is
For example, the period may be about 1 to 14 days, preferably about 3 to 14 days, although it can be changed as appropriate depending on the condition of acne on the back, age, sex, etc. of the subject.

The drug for preventing and/or treating back acne of the present invention can be produced by a known method. A sterilization step can be included if necessary.

The drug for preventing and/or treating acne for the back of the present invention is formulated by mixing it with a known base or carrier that can be used as a pharmaceutical, quasi-drug, cosmetic, etc., to the extent that the effects of the present invention are not impaired. can do. In addition, the back acne prevention and/or treatment agent of the present invention includes, for example, surfactants, oils, alcohols, thickeners, preservatives, antioxidants, preservatives, chelating agents, Additives such as pH adjusters, stabilizers, solubilizers, suspending agents, tonicity agents, buffers, soothing agents, dispersants, fragrances, colorants, pigments, water, etc. can be added. . These additives can be used alone or in combination of two or more.

As a base or carrier, hydrocarbons such as liquid paraffin, squalane, gelled hydrocarbons (such as plastibase), ozokerite, α-olefin oligomers, light liquid paraffins; methylpolysiloxane, crosslinked methylpolysiloxane, highly polymerized methyl Polysiloxane, cyclic silicone, alkyl-modified silicone, cross-linked alkyl-modified silicone, amino-modified silicone, polyether-modified silicone, polyglycerin-modified silicone, cross-linked polyether-modified silicone, cross-linked alkyl polyether-modified silicone, silicone/alkyl chain combination Modified polyether-modified silicone, silicone-alkyl chain co-modified polyglycerin-modified silicone, polyether-modified branched silicone, polyglycerin-modified branched silicone, acrylic silicone, phenyl-modified silicone, silicone oil such as silicone resin; polyethylene glycol; dioxane; myristin Esters such as isopropyl acid, octyldodecyl myristate, isopropyl palmitate, cetyl palmitate, isononyl isononanoate, pentaerythritol tetra-2-ethylhexanoate; lower alcohols such as ethanol, isopropanol; diethylene glycol monomethyl ether, diethylene glycol mono Glycol ethers such as ethyl ether; polyethylene glycol, propylene glycol, 1,3-butylene glycol, glycerin,
Polyhydric alcohols such as isoprene glycol; aqueous bases such as water, and the like. From the viewpoint of stably exhibiting the effects of the present invention, the base or carrier is preferably 1,3-butylene glycol and/or glycerin.

One type of base or carrier can be used alone or two or more types can be used in combination.

Examples of the surfactant include sorbitan monoisostearate, sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate, diglycerol sorbitan pent-2-ethylhexylate, and diglycerol sorbitan tetra-2-ethylhexylate. sorbitan fatty acid esters; propylene glycol fatty acid esters such as propylene glycol monostearate; polyoxyethylene hydrogenated castor oil 4
Hydrogenated castor oil derivatives such as 0 (HCO-40), polyoxyethylene hydrogenated castor oil 50 (HCO-50), polyoxyethylene hydrogenated castor oil 60 (HCO-60), and polyoxyethylene hydrogenated castor oil 80; monolauric acid Polyoxyethylene (20) Sorbitan (Polysorbate 20), Polyoxyethylene Monostearate (20) Sorbitan (Polysorbate 60), Polyoxyethylene Monooleate (20) Sorbitan (Polysorbate 80), Polyoxyethylene Isostearate (20) Polyoxyethylene sorbitan fatty acid esters such as sorbitan; polyoxyethylene monococonut fatty acid glyceryl;
Glycerin alkyl ethers; alkyl glucosides; polyoxyalkylene alkyl ethers such as polyoxyethylene (20) oleyl ether, polyoxyethylene cetyl ether, and polyoxyethylene (9) lauryl ether; amines such as stearylamine and oleylamine; Silicone surfactants such as oxyethylene/methylpolysiloxane copolymer, lauryl PEG-9 polydimethylsiloxyethyl dimethicone, PEG-9 polydimethylsiloxyethyl dimethicone; laurate, palmitate, cocoyl glutamate, coco Anionic surfactants such as oil methyl alanine salt, acyl methyl taurate salt, polyoxyethylene lauryl sulfate, amphoteric surfactant such as lauryl diaminoethyl glycine salt, coconut oil fatty acid betaine salt, polyoxyethylene lauryl alcohol ether, etc. Examples include nonionic surfactants such as In addition, in this specification,
Polyoxyethylene is also written as "POE", and the number in parentheses indicates the number of moles of ethylene oxide added.

Examples of the oil include natural animal and vegetable oils and fats, hydrocarbon oils, ester oils, silicone oils, higher alcohols, higher fatty acids, animal and vegetable oils, and synthetic essential oils.

Examples of natural animal and vegetable oils include avocado oil, flaxseed oil, almond oil, olive oil, cacao oil, beef tallow, tung oil, wheat germ oil, sesame oil, rice germ oil, rice bran oil, safflower oil,
Soybean oil, evening primrose oil, camellia oil, corn oil, rapeseed oil, horse tallow, persic oil, palm oil, palm kernel oil, castor oil, sunflower oil, lard, grape oil, jojoba oil, macadamia nut oil, mink oil, cottonseed oil , Japanese blackberry, coconut oil, hydrogenated coconut oil, peanut oil, lanolin, egg yolk oil,
Examples include rosehip oil.

As the hydrocarbon oil, paraffinic hydrocarbons and olefinic hydrocarbons are used, and examples thereof include squalane, squalene, ceresin, paraffin, pristane, microcrystalline wax, liquid paraffin, and vaseline.

As the ester oil, synthetic esters and esters of higher alcohols and higher fatty acids are used, such as diisobutyl adipate, 2-hexyldecyl adipate, di-2-heptyl undecyl adipate, isostearyl isostearate, Trimethylolpropane triisostearate, cetyl 2-ethylhexanoate, neopentyl glycol di-2-ethylhexanoate, trimethylolpropane tri-2-ethylhexanoate, tetra-
Pentaerythritol 2-ethylhexanoate, cetyl octoate, oleyl oleate,
Octyldodecyl oleate, decyl oleate, neopentyl glycol dicaprate, 2-ethylhexyl succinate, isocetyl stearate, butyl stearate, diisopropyl sebacate, cetyl lactate, tetradecyl lactate, isopropyl myristate, octyldodecyl myristate, myristic acid Cetyl, myristyl myristate, octyl palmitate, 2-ethylhexyl palmitate, 2-hexyldecyl palmitate, 2-heptyl undecyl palmitate, cholesteryl 12-hydroxystearate, phytosteryl oleate, diisostearyl malate, paramethoxy Examples include cinnamate ester, pentaerythritol tetrarosinate, and the like.

Examples of the silicone oil include dimethylpolysiloxane, highly polymerized methylpolysiloxane, methylphenylpolysiloxane, methylhydrogenpolysiloxane, octamethylcyclotetrasiloxane, octamethylcyclopentasiloxane, decamethylcyclohexasiloxane, stearoxysilicone, etc. Examples include higher alkoxy-modified silicones, alkyl-modified silicones, and higher fatty acid ester-modified silicones.

Examples of the higher alcohol include octyldodecanol, isostearyl alcohol, oleyl alcohol, stearyl alcohol, cetanol, and behenyl alcohol.

As the higher fatty acid, saturated or unsaturated linear or branched fatty acids having 12 to 22 carbon atoms can be used, such as isostearic acid, oxystearic acid, oleic acid,
Examples include stearic acid, palmitic acid, behenic acid, myristic acid, lauric acid, lanolic acid, linoleic acid, and linolenic acid.

Examples of thickeners include guar gum, locust bean gum, carrageenan, xanthan gum, carboxymethylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose,
Hydrophobized hydroxypropyl methylcellulose, polyvinyl alcohol, polyvinylpyrrolidone, carboxyvinyl polymer, alkyl acrylate methacrylate copolymer, polyethylene glycol, bentonite, (hydroxyethyl acrylate/Na acryloyldimethyltaurine) copolymer, (ammonium acryloyldimethyltaurate/vinyl) pyrrolidone) copolymer, etc.

Suitable examples of preservatives include paraoxybenzoic acid esters, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, sorbic acid, and the like.

Suitable examples of antioxidants include sulfites, ascorbic acid, and the like.

Examples of antioxidants include dibutylhydroxytoluene (BHT), butylhydroxyanisole, sorbic acid, sodium sulfite, ascorbic acid, erythorbic acid, and L-cysteine hydrochloride.

Preservatives include benzoic acid, sodium benzoate, dehydroacetic acid, sodium dehydroacetate, isobutyl paraoxybenzoate, isopropyl paraoxybenzoate, butyl paraoxybenzoate, ethyl paraoxybenzoate, propyl paraoxybenzoate, benzyl paraoxybenzoate, paraoxybenzoate. Examples include methyl benzoate and phenoxyethanol.

Examples of the chelating agent include EDTA disodium salt, EDTA calcium disodium salt, and the like. From the viewpoint of significantly exerting the effects of the present invention, it is preferable that the drug for preventing and/or treating acne for back of the present invention further contains EDTA disodium salt.

Examples of pH adjusters include inorganic acids (hydrochloric acid, sulfuric acid, etc.), organic acids (lactic acid, sodium lactate, citric acid, sodium citrate, succinic acid, sodium succinate, etc.), inorganic bases (potassium hydroxide, sodium hydroxide, etc.) ), organic bases (triethanolamine, diisopropanolamine, triisopropanolamine, etc.), and the like.

Examples of the stabilizer include sodium polyacrylate, dibutylhydroxytoluene, butylhydroxyanisole, and the like.

Suitable examples of solubilizing agents include polyethylene glycol, propylene glycol, D-mannitol, benzyl benzoate, ethanol, trisaminomethane, cholesterol, triethanolamine, sodium carbonate, sodium citrate, and the like.

Suitable examples of suspending agents include surfactants such as stearyltriethanolamine, sodium lauryl sulfate, lauryl aminopropionic acid, lecithin, benzalkonium chloride, benzethonium chloride, and glyceryl monostearate; for example, polyvinyl alcohol; Examples include hydrophilic polymers such as polyvinylpyrrolidone, sodium carboxymethylcellulose, methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, and hydroxypropylcellulose.

Suitable examples of tonicity agents include sodium chloride, glycerin, D-mannitol, and the like.

Suitable examples of buffers include buffers such as phosphate, acetate, carbonate, and citrate.

Suitable examples of soothing agents include benzyl alcohol and the like.

Examples of the dispersant include sodium pyrophosphate, sodium hexametaphosphate, polyvinyl alcohol, polyvinylpyrrolidone, methyl vinyl ether/maleic anhydride crosslinked copolymer, and organic acids.

Examples of the coloring agent include inorganic pigments and natural pigments.

The drug for preventing and/or treating back acne of the present invention may contain other active ingredients within a range that does not impair the effects of the present invention. Specific examples of active ingredients include moisturizing ingredients, pearlescent agents, conditioning agents, scrubbing agents, blood circulation promoting ingredients, astringent ingredients, ultraviolet absorbing ingredients, ultraviolet scattering ingredients, cleaning ingredients, antibacterial ingredients, anti-inflammatory agents, and vitamins. peptides or derivatives thereof, amino acids or derivatives thereof, cell activation components, etc.

Moisturizing ingredients include polyhydric alcohols such as glycerin, 1,3-butylene glycol, propylene glycol, polyethylene glycol, and diglycerin; saccharides such as trehalose, xylitol, and oligosaccharides; sodium hyaluronate, heparin-like substances, and chondroitin sulfate. Polymer compounds such as sodium, collagen, elastin, keratin, chitin, and chitosan; amino acids such as glycine, aspartic acid, and arginine; natural moisturizing factors such as sodium lactate, urea, and sodium pyrrolidone carboxylate; ceramide, cholesterol, and phosphorus. Lipids such as lipids; examples include plant extracts such as chamomile extract, Hamamelis extract, tea extract, and perilla extract. From the viewpoint of stably exhibiting the effects of the present invention, the moisturizing component is preferably glycerin and/or 1,3-butylene glycol.

Examples of the pearl luster imparting agent include ethylene glycol distearate, ethylene glycol monostearate, and triethylene glycol distearate.

Conditioning agents include, for example, cationized cellulose, cationized starch, cationized fenugreek gum, cationized guar gum, cationized tara gum, cationized locust bean gum, cationized xanthan gum, diallyl quaternary ammonium salt/acrylamide copolymer, polyquaternium , vinylimidazolium trichloride/vinylpyrrolidone copolymer, hydroxyethylcellulose/dimethyldiallylammonium chloride copolymer, vinylpyrrolidone/quaternized dimethylaminoethyl methacrylate copolymer, polyvinylpyrrolidone/alkylaminoacrylate copolymer, polyvinylpyrrolidone /alkylaminoacrylate/vinylcaprolactam copolymer, vinylpyrrolidone/
Examples include methacrylamide propyl trimethylammonium chloride copolymer, alkylacrylamide/acrylate/alkylaminoalkylacrylamide/polyethylene glycol methacrylate copolymer, and adipic acid/dimethylaminohydroxypropylethylenetriamine copolymer.

Examples of the scrubbing agent include apricot kernel powder, almond shell powder, apricot kernel powder, sodium chloride particles, olive kernel powder, dried seawater particles, candelilla wax, walnut shell powder, cherry kernel powder, coral powder, charcoal powder, Examples include hazel shell powder, polyethylene powder, and silicic anhydride.

Examples of blood circulation promoters include acetylcholine, ictamol, caffeine, capsaicin, canthalys tincture, gamma oryzanol, shokyo tincture, zingerone,
Examples include cephalanthine, Oriental japonica extract, tannic acid, capsicum tincture, tolazoline, tocopherol nicotinate, benzyl nicotinate, and the like.

Astringent components include zinc sulfate, hydroxyaluminum, aluminum chloride, zinc sulfophosphate, and tannic acid.

The ultraviolet absorbing components include octyl triazone, diethylaminohydroxybenzoylhexyl benzoate, dimethoxybenzylidene dioxoimidazolidine octyl propionate, 2-ethylhexyl paramethoxycinnamate, t-butylmethoxydibenzoylmethane, phenylbenzimidazole sulfonic acid, Examples include octyl methoxycinnamate and ethylhexyl methoxycinnamate.

Ultraviolet scattering components include hydrated silicic acid, zinc silicate, cerium silicate, titanium silicate,
Inorganic compounds such as zinc oxide, zirconium oxide, cerium oxide, titanium oxide, iron oxide, and anhydrous silicic acid, coating these inorganic compounds with inorganic powder such as hydrous silicic acid, aluminum hydroxide, mica, and talc, Examples include those composited with resin powder such as polyethylene, polyester, polystyrene, and nylon, and those treated with silicone oil, fatty acid aluminum salt, etc.

Cleaning ingredients include alkali metal salts such as potassium laurate, potassium myristate, potassium palmitate, or potassium stearate, soaps such as alkanolamide salts or amino acid salts, and amino acid interfaces such as sodium cocoyl glutamate and sodium cocoyl methyl taurate. Activators, ether sulfate ester salts such as sodium laureth sulfate, ether carboxylates such as sodium lauryl ether acetate, sulfosuccinate ester salts such as sodium alkyl sulfosuccinate, coconut oil fatty acid monoethanolamide, coconut oil fatty acid ethanolamide fatty acid alkanolamides such as sodium lauryl phosphate, monoalkyl phosphate ester salts such as sodium polyoxyethylene lauryl ether phosphate, coconut oil fatty acid amidopropyldimethylaminoacetic acid betaine, lauryldimethylaminoacetic acid betaine, 2-alkyl-N- Betaine-type amphoteric surfactants such as carboxymethyl-N-hydroxyethylimidazolinium betaine, laurylhydroxysulfobetaine and lauroylamidoethylhydroxyethylcarboxymethylbetaine sodium hydroxypropyl phosphate, amino acid type amphoteric surfactants such as sodium lauryl aminopropionate Examples include activators.

Antibacterial ingredients include chlorhexidine, benzalkonium chloride, acrinol, ethanol, benzethonium chloride, cresol, gluconic acid and its derivatives, povidone iodine,
Potassium iodide, iodine, triclocarban, triclosan, Photosensor No. 101, Photosensor 2
No. 01, paraben, phenoxyethanol, 1,2-pentanediol, alkyldiaminoglycine hydrochloride, piroctoolamine, miconazole and the like.

As the anti-inflammatory agent, either a steroidal anti-inflammatory agent or a non-steroidal anti-inflammatory agent can be used. Specific examples include, but are not limited to, dexamethasone acetate valerate, dexamethasone, prodnisolone valerate acetate (prednisolone valerate acetate), prodnisolone acetate, prodnisolone, hydrocortisone acetate, hydrocortisone, ufenamate, bufexamac, etc. Further examples include diclofenac, piroxicam, epsilon-aminocaproic acid, bromelain, serrapeptase, semi-alkaline proteinase, and pharmaceutically acceptable salts thereof. When using a steroid-based anti-inflammatory agent as an anti-inflammatory agent, an antedrug steroid such as prednisolone valerate acetate (PVA), which exhibits pharmacological activity in the affected area where it is applied and is metabolized into a less active substance in the body, is suitable. used for.

Examples of vitamins include vitamin E such as dl-α-tocopherol, dl-α-tocopherol succinate, and dl-α-tocopherol calcium succinate; riboflavin, flavin mononucleotide, flavin adenine dinucleotide, riboflavin butyrate,
Vitamin B2 such as riboflavin tetrabutyrate, sodium riboflavin 5'-phosphate, riboflavin tetranicotinate; dl-α-tocopherol nicotinate, benzyl nicotinate, methyl nicotinate, β-butoxyethyl nicotinate, nicotinic acid Nicotinic acids such as 1-(4-methylphenyl)ethyl; Vitamin C such as ascorbigen-A, ascorbic acid stearate, ascorbyl palmitate, and L-ascorbyl dipalmitate; methylhesperidin, ergocalciferol, and cholesterin. Vitamin D such as calciferol; Vitamin K such as phylloquinone and farnoquinone, γ-oryzanol, dibenzoylthiamine, dibenzoylthiamine hydrochloride; thiamine hydrochloride, thiamine cetyl hydrochloride, thiamine thiocyanate, thiamine lauryl hydrochloride, Thiamine nitrate, thiamine monophosphate, thiamine lysine salt, thiamine triphosphate,
Vitamin B1 such as thiamine monophosphate ester phosphate, thiamine monophosphate ester, thiamine diphosphate ester, thiamine diphosphate ester hydrochloride, thiamine triphosphate, thiamine triphosphate monophosphate; pyridoxine hydrochloride, pyridoxine acetate, hydrochloric acid Vitamin B6 such as pyridoxal, pyridoxal 5'-phosphate, and pyridoxamine hydrochloride; Vitamin B12 such as cyanocobalamin, hydroxocobalamin, and deoxyadenosylcobalamin; Folic acids such as folic acid and pteroylglutamic acid; Nicotinic acid, nicotinamide, etc. Nicotinic acids; pantothenic acids such as pantothenic acid, calcium pantothenate, pantothenyl alcohol (panthenol), D-panthesain, D-pantethine, coenzyme A, pantothenyl ethyl ether; biotins such as biotin and biotisin; ascorbic acid Vitamin C, which is an ascorbic acid derivative such as , sodium ascorbate, dehydroascorbic acid, sodium ascorbic acid phosphate, and magnesium ascorbic acid phosphate; vitamin-like action of carnitine, ferulic acid, α-lipoic acid, orotic acid, etc. Examples include factors.

Examples of peptides or derivatives thereof include keratin-degrading peptides, hydrolyzed keratin, collagen, fish-derived collagen, atelocollagen, gelatin, elastin, elastin-degrading peptides, collagen-degrading peptides, hydrolyzed collagen, hydroxypropylammonium chloride hydrolyzed collagen, and elastin-degrading peptides. , conchiolin degradable peptide, hydrolyzed conchiolin, silk proteolytic peptide, hydrolyzed silk, lauroyl hydrolyzed silk sodium, soybean proteolytic peptide, hydrolyzed soy protein, wheat protein, wheat proteolytic peptide, hydrolyzed wheat protein, caseinolytic peptide , acylated peptides (palmitoyl oligopeptide, palmitoyl pentapeptide, palmitoyl tetrapeptide, etc.).

Amino acids or derivatives thereof include betaine (trimethylglycine), proline, hydroxyproline, arginine, lysine, serine, glycine, alanine, phenylalanine, β-alanine, threonine, glutamic acid, glutamine, asparagine, aspartic acid, cysteine, cystine, methionine. , leucine, isoleucine, valine, histidine, taurine, γ-aminobutyric acid, γ-amino-β-hydroxybutyric acid, carnitine, carnosine, creatine and the like.

Cell activating ingredients include amino acids such as γ-aminobutyric acid and ε-aminocaproic acid, vitamins such as retinol, thiamine, riboflavin, pyridoxine hydrochloride, and pantothenic acids, α-hydroxy acids such as glycolic acid and lactic acid, tannins, Examples include flavonoids, saponins, Photosensor No. 301, and the like.

[External composition for inhibiting the growth of Malassezia fungi on the back]
In another embodiment, the invention provides (A) salicylic acid and its salts, isopropylmethylphenol, sulfur, resorcinol, ibuprofenpiconol, dipotassium glycyrrhizinate, glycyrrhetinic acid, allantoin, zinc oxide, diphenhydramine, homosulfamine, sulfadiazine, and It is possible to provide an external composition for inhibiting the growth of Malassezia fungi on the back, which contains at least one selected from the group consisting of tocopherol acetate and (B) ethanol in an amount of less than 22.84% by weight. . Component (A), component (B), other components, dosage form, etc. used in such an external composition are the same as those for [back acne prevention and/or treatment drug].

As used herein, "suppressing the growth of Malassezia fungi" refers to suppressing the growth of Malassezia fungi, including preventing or decreasing the number of viable Malassezia fungi, and sterilizing Malassezia fungi. including doing. For example, as shown in the Examples, the size of the inhibition zone (
Diffusion method (perforated plate method)) is increased compared to the comparative example containing 22.84% ethanol.

Next, the present invention will be specifically explained with reference to Examples and Test Examples, but the present invention is not limited to the following Examples and Test Examples.

[Test Example 1-1. Sebum compatibility test 1]
The effect of setting the amount of (B) ethanol in the composition to less than 22.84% by weight on the compatibility with sebum was investigated. In order to strictly examine the influence of ethanol concentration, each sample does not contain component (A), but even if the sample contains component (A),
It is assumed that this has no effect on the trends shown in the results.

Each composition shown in Table 2 was stirred using a stirrer (500 rpm, 15 minutes, room temperature) to prepare a test sample.

0.01 g of the artificial sebum shown in Table 3 was applied uniformly onto a slide glass in an area of 1 cm x 2 cm, and the weight (X) of each slide glass was measured. 50 m filled with 15 ml of each sample
A slide glass coated with artificial sebum was placed in a tube and shaken at 180 r/min and an amplitude of 30 mm for 1 minute using a DOUBLE SHAKER NR-30 (TAITEC).
Pull out the glass slide vertically. The surface coated with artificial sebum was turned up and dried overnight at room temperature. Measure the weight (Y) of the slide glass after drying, and calculate the amount of artificial sebum that has fallen (g) = (X)
-(Y) was calculated, and the larger this value, the better the sebum compatibility. If the sebum is compatible with the skin,
Expected to have a degreasing effect. The results are shown in FIG.

As shown in Figure 1, a new problem was found in the sample (B) containing 22.84% by weight of ethanol (Reference Comparative Example 1): poor sebum compatibility and insufficient removal of sebum. It was done. On the other hand, it has been revealed that (B) ethanol at less than 22.84% by weight improves sebum compatibility and is effective in removing sebum (Reference Examples 1 to 3). By including component (A) in Reference Examples 1 to 3, it is possible to allow component (A) to act while alleviating sebum blockage in hair follicles, making it more effective against acne on the back. It is hoped that prevention and treatment will be possible.

[Test Example 1-2. Sebum compatibility test 2]
Each composition shown in Table 4 was prepared in the same manner as in Test Example 1-1 and used as a test sample. (
In a composition containing component A) and containing less than 22.84% by weight of (B) ethanol,
The effect on compatibility with sebum was investigated. The test method was the same as Test Example 1-1. The results are shown in FIG.

As shown in FIG. 2, even for the sample containing salicylic acid as component (A), results showing the same tendency as Test Example 1-1 were obtained. Specifically, in the sample containing 22.84% by weight of component (A) and ethanol (B) (Comparative Example 1), sebum compatibility decreased;
While sebum removal was insufficient, in Examples 1 and 2 containing component (A) and (B) less than 22.84% by weight of ethanol, sebum compatibility was improved. Shown.

[Test Example 1-3. Sebum compatibility test 3]
Each composition shown in Table 5 was prepared in the same manner as Test Example 1-1 and used as a test sample. (
In a composition containing component A) and containing less than 22.84% by weight of (B) ethanol,
The effect on compatibility with sebum was investigated. The test method was the same as Test Example 1-1. The results are shown in FIG.

As shown in FIG. 3, even for the sample containing salicylic acid as component (A), results showing the same tendency as Test Example 1-1 were obtained. Specifically, in the sample containing 22.84% by weight of component (A) and ethanol (B) (Comparative Example 2), sebum compatibility decreased;
In contrast to insufficient removal of sebum, Examples 3 to 5 containing component (A) and (B) less than 22.84% by weight of ethanol were shown to improve compatibility with sebum. Ta.

[Test Example 1-4. Sebum compatibility test 4]
Each composition shown in Table 6 was prepared in the same manner as in Test Example 1-1 and used as a test sample. (
In a composition containing component A) and containing less than 22.84% by weight of (B) ethanol,
The effect on compatibility with sebum was investigated. The test method was the same as Test Example 1-1. The results are shown in FIG.

As shown in FIG. 4, even if the sample contains IPMP as the component (A),
Results showing the same tendency as Test Example 1-1 were obtained. Specifically, in the sample containing 22.84% by weight of component (A) and ethanol (B) (Comparative Example 3), sebum compatibility decreased and sebum removal was insufficient. Examples 6 to 8 containing component (A) and (B) less than 22.84% by weight of ethanol were shown to have improved sebum compatibility.

[Test Example 1-5. Sebum compatibility test 5]
Each composition shown in Table 7 was prepared in the same manner as in Test Example 1-1 and used as a test sample. (
In a composition containing component A) and containing less than 22.84% by weight of (B) ethanol,
The effect on compatibility with sebum was investigated. The test method was the same as Test Example 1-1. The results are shown in FIG.

As shown in FIG. 5, even for the sample containing ibuprofen piconol as component (A), results showing the same tendency as Test Example 1-1 were obtained. Specifically, (A)
In the sample containing 22.84% by weight of component (A) and (B) ethanol (Comparative Example 4), sebum compatibility decreased and sebum removal was insufficient, whereas component (A) and (B) 22.84
Examples 9 to 11 containing less than % by weight of ethanol were shown to have improved sebum compatibility.

[Test Example 1-6. Sebum compatibility test 6]
Each composition shown in Table 8 was prepared in the same manner as in Test Example 1-1 and used as a test sample. (
In a composition containing component A) and containing less than 22.84% by weight of (B) ethanol,
The effect on compatibility with sebum was investigated. The test method was the same as Test Example 1-1. The results are shown in FIG.

As shown in FIG. 6, even for the sample containing allantoin as the component (A), results showing the same tendency as Test Example 1-1 were obtained. Specifically, (A) component and (B)
In the sample containing 22.84% by weight of ethanol (Comparative Example 5), the blending with sebum decreased and the removal of sebum was insufficient, whereas component (A) and 22.84% by weight of (B) In Examples 12 to 14 containing less than 20% of ethanol, it was shown that sebum compatibility was improved.

[Test Example 1-7. Sebum compatibility test 7]
Each composition shown in Table 9 was prepared in the same manner as in Test Example 1-1 and used as a test sample. (
In a composition containing component A) and containing less than 22.84% by weight of (B) ethanol,
The effect on compatibility with sebum was investigated. The test method was the same as Test Example 1-1. The results are shown in FIG.

As shown in FIG. 7, even with the sample containing glycyrrhetinic acid as component (A), results showing the same tendency as Test Example 1-1 were obtained. Specifically, component (A) and (
B) In the sample containing 22.84% by weight of ethanol (Comparative Example 6), the compatibility with sebum decreased and the removal of sebum was insufficient, whereas component (A) and (B) 22.84% by weight Examples 15 to 17 containing less than % by weight of ethanol were shown to have improved sebum compatibility.

[Test Example 1-8. Sebum compatibility test 8]
Each composition shown in Table 10 was prepared in the same manner as Test Example 1-1 and used as a test sample.
The influence of a composition containing component (A) and less than 22.84% by weight of ethanol (B) on its compatibility with sebum was investigated. The test method was the same as Test Example 1-1. The results are shown in FIG.

As shown in FIG. 8, even with the sample containing sulfur as component (A), results showing the same tendency as Test Example 1-1 were obtained. Specifically, in the sample containing 22.84% by weight of component (A) and ethanol (B) (Comparative Example 7), sebum compatibility decreased and sebum removal was insufficient. Examples 18 to 20 containing component (A) and (B) less than 22.84% by weight of ethanol were shown to have improved sebum compatibility.

[Test Example 1-9. Sebum compatibility test 9]
Each composition shown in Table 11 was prepared in the same manner as Test Example 1-1 and used as a test sample.
The influence of a composition containing component (A) and less than 22.84% by weight of ethanol (B) on its compatibility with sebum was investigated. The test method was the same as Test Example 1-1. The results are shown in FIG.

As shown in FIG. 9, even with the sample containing resorcinol as component (A), results showing the same tendency as Test Example 1-1 were obtained. Specifically, in the sample containing 22.84% by weight of component (A) and ethanol (B) (Comparative Example 8), sebum compatibility decreased;
While sebum removal was insufficient, Examples 21 to 23 containing component (A) and (B) less than 22.84% by weight of ethanol showed improved sebum compatibility. Ta.

[Test Example 1-10. Sebum compatibility test 10]
Each composition shown in Table 12 was prepared in the same manner as in Test Example 1-1 and used as a test sample.
The influence of a composition containing component (A) and less than 22.84% by weight of ethanol (B) on its compatibility with sebum was investigated. The test method was the same as Test Example 1-1. The results are shown in FIG. However, if the value of the amount of artificial sebum dropped due to a quantitative error was negative, that value was regarded as 0.

As shown in FIG. 10, even with the sample containing tocopherol acetate as component (A), results showing the same tendency as Test Example 1-1 were obtained. in particular,(
In the sample containing 22.84% by weight of component A) and ethanol (B) (Comparative Example 9), the blending with sebum decreased and sebum removal was insufficient, whereas component (A) and ( B)22.
Examples 24 and 25 containing less than 84% by weight of ethanol were shown to have improved sebum compatibility.

[Test Example 1-11. Sebum compatibility test 11]
Each composition shown in Table 13 was prepared in the same manner as Test Example 1-1 and used as a test sample.
The influence of a composition containing component (A) and less than 22.84% by weight of ethanol (B) on its compatibility with sebum was investigated. The test method was the same as Test Example 1-1. The results are shown in FIG.

As shown in FIG. 11, even with the sample containing POE(9) lauryl ether as a surfactant, results showing the same tendency as Test Example 1-1 were obtained. in particular,
Samples containing 22.84% by weight of component (A) and (B) ethanol (Comparative Examples 10 to 12)
), the compatibility with sebum decreased and sebum removal was insufficient, whereas component (A) and (
B) Examples 26 to 31 containing less than 22.84% by weight of ethanol showed improved sebum compatibility.

[Test Example 2. Inhibition circle test]
In order to evaluate the growth inhibition effect on acne-causing bacteria, the following diffusion method (perforated plate method) was used.
A test was conducted. The following tests were conducted using three types of fungi of the genus Malassezia among acne-causing bacteria. The compositions listed in Table 14 were used as Comparative Examples 13 to 15 and Example 32. Comparative Example 13 is a brand name: Cenacure (manufactured by Kobayashi Pharmaceutical Co., Ltd.), which has an ethanol content of 22.84% and is intended for back acne, and in addition to the active ingredients and purified water listed in Table 14, was added. BG (butylene glycol), concentrated glycerin, parabens, EDTA-Na and p
Contains H regulator. In Comparative Example 14, in addition to the active ingredients listed in Table 14, as additives,
Contains BG, parabens and xanthan gum. Comparative Example 15 did not contain any additives other than the active ingredients and purified water listed in Table 14. Example 32 contains, in addition to the active ingredients and purified water listed in Table 14, additives such as EDTA-Na, pH adjuster, xanthan gum, polyoxyethylene hydrogenated castor oil, polysorbate 20, L-arginine, chlorobutanol, and nicotine. Contains acid amide and fragrance.

One type of Malassezia fungus (M. furfur (ATCC: 46266)) was prepared,
PM medium (ATCC medium: ¹⁰⁷²
Pityrosporum medium) was prepared. Separately, two other types of Malassezia fungi (M. restricta (ATCC: MYA-4611), M. globos
a (ATCC: MYA-4612)) was prepared, and MLNA medium (ATCC Medium: 2737 Leeming & Not) inoculated with each bacterial solution at approximately 10 ⁶ CFU/mL was prepared.
Managar Modified MLNA media) was created. A hole with a diameter of 8 mm was made in each medium using a sterilized hole cutter (manufactured by TOYOBO, Biopsy Punch 8 mm, stainless steel). Each composition (Comparative Examples 13 to 15, Example 32) was injected into the hole completely (approximately 0.1 g). After that, M. The PM medium inoculated with M. furfur was cultured under aerobic conditions at 33°C for 6 days. restricta or M. The MLNA medium inoculated with S. globosa was cultured under aerobic conditions at 33°C for 10 days. At the end of the culture period, the diameter of each inhibition circle (
The size (mm) was measured, and the average value (n=3) was calculated for each Malassezia fungal species. The results are shown in FIG. 12 below.

As shown in FIG. 12, in Example 32 containing component (A) and (B) less than 22.84% by weight of ethanol, unexpectedly, M. furfur, M. restricta
Not only M. It showed remarkable antibacterial effects against all three bacterial species including S. globosa. In Comparative Examples 13 and 14, which share some of the active ingredients but have an ethanol content of 22.84% by weight or more, M. furfur, M. The antibacterial effect against M. restricta is low, and the antibacterial effect against M. restricta is low. No antibacterial effect against S. globosa was observed (inhibition circle size was 8 mm). M. Since S. globosa is a bacterial species that is suspected to be the causative agent of Malassezia folliculitis, which is a type of acne on the back, Example 32 is expected to have a remarkable effect on the prevention and/or treatment of acne on the back. be done. In addition, in Comparative Example 15 in which the content of ethanol was 100% by weight, no antibacterial effect was observed against all three bacterial species.

[Test Example 3-1. Sensory test 1]
In the same manner as Test Example 1-1, the compositions shown in Table 15 were prepared and used as test samples. Sensory evaluation was performed for each test sample.

Specifically, before the test, the backs and arms of the test subjects (3 healthy subjects) were wiped and dried for 5 minutes. Each test sample contained in a spray container was sprayed twice (approximately 0.3 g) on the back and arms before being dressed. Five minutes after spraying, the evaluation items of "stimulation (tingling sensation)", "hot flashes", "tightness", "itching", and "uncomfortable feeling" were evaluated according to the following evaluation criteria, and the average value of the scores was calculated. Figure 13 shows the results for “stimulation (tingling sensation)” and “hot flashes”.
The results for "Tightness" are shown in FIG. 14, the results for "Tension" are shown in FIG. 15, the results for "Itching" are shown in FIG. 16, and the results for "Uncomfortable feeling" are shown in FIG. 17.

Evaluation criteria
<5>I feel it very much
<4>I feel a little
<3>Can't say either way
<2>I don't feel much
<1>I don't feel it at all

As shown in FIGS. 13 to 17, in Comparative Example 16 in which the ethanol content was 22.84% by weight or more, when applied to the back, 5 minutes after spraying, there was a feeling of irritation (FIG. 13), hot flashes ( The results were that the patient felt tingling (Fig. 14), tingling (Fig. 15), itching (Fig. 16), and discomfort (Fig. 17). When Comparative Example 16 was applied to the arm, no irritation, hot flashes, tightness, itching, or discomfort were felt, indicating that the above-mentioned feeling of use was a problem unique to the back.

Although not limited to this, it is presumed that the above-mentioned problem arises because the back of the wearer does not have an open opening like a sleeve, unlike the arms. In particular, irritation and itching are undesirable because they may lead to acne itching on the back. Furthermore, if hot flashes are caused by an increase in body temperature or humidity, this is not preferable because it may promote the growth of acne-causing bacteria on the back.

On the other hand, Example 3 containing component (A) and (B) less than 22.84% by weight of ethanol
3 and Example 34, 5 minutes after spraying, no irritation (Figure 13), hot flashes (Figure 14), tightness (Figure 15), itching (Figure 16), or discomfort (Figure 17) were felt. The results were obtained. Further, in Reference Example 4 which did not contain ethanol, the same results as in Examples 33 and 34 were obtained. It is presumed that even if component (A) is included in Reference Example 4, similar results will be obtained.

[Test Example 3-2. Sensory test 2]
In the same manner as Test Example 1-1, the compositions shown in Table 16 were prepared and used as test samples. Sensory evaluation was performed for each test sample. The test method is the same as Test Example 3-1. Figure 18 shows the results for "stimulation," Figure 19 shows the results for "hot flashes," Figure 20 shows the results for "tension," Figure 21 shows the results for "itch," and Figure 21 shows the results for "unnatural feeling." The results are shown in FIG. 22.

As shown in FIGS. 18 to 22, in Comparative Example 17 in which the ethanol content was 22.84% by weight or more, when applied to the back, 5 minutes after spraying, there was a feeling of irritation (FIG. 18), hot flashes ( The results showed that the patient felt tingling (Fig. 19), tingling (Fig. 20), itching (Fig. 21), and discomfort (Fig. 22). When Comparative Example 17 was applied to the arm, no irritation, hot flashes, tightness, itching, or discomfort were felt, indicating that the above-mentioned feeling of use was a problem unique to the back.

On the other hand, Example 3 containing component (A) and (B) less than 22.84% by weight of ethanol
5 and Example 36, 5 minutes after spraying, no irritation (Figure 18), hot flashes (Figure 19), tightness (Figure 20), itching (Figure 21), or discomfort (Figure 22) were felt. The results were obtained.

[Test Example 3-3. Sensory test 3]
In the same manner as Test Example 1-1, the compositions shown in Table 17 were prepared and used as test samples. Sensory evaluation was performed for each test sample. The test method is the same as Test Example 3-1. Figure 23 shows the results for "stimulation," Figure 24 shows the results for "hot flashes," Figure 25 shows the results for "tension," Figure 26 shows the results for "itch," and Figure 26 shows the results for "unnatural feeling." The results are shown in FIG. 27.

As shown in FIGS. 23 to 27, in Comparative Example 18 in which the ethanol content was 22.84% by weight or more, when applied to the back, 5 minutes after spraying, there was a feeling of irritation (FIG. 23), hot flashes ( The results were that the patient felt tingling (Fig. 24), tingling (Fig. 25), itching (Fig. 26), and discomfort (Fig. 27). When Comparative Example 18 was applied to the arm, no irritation, hot flashes, tightness, itching, or discomfort were felt, indicating that the above-mentioned feeling of use was a problem unique to the back.

On the other hand, Example 3 containing component (A) and (B) less than 22.84% by weight of ethanol
7 and Example 38, 5 minutes after spraying, no irritation (Fig. 23), hot flashes (Fig. 24), tightness (Fig. 25), itching (Fig. 26), or discomfort (Fig. 27) were felt. The results were obtained.

[Test Example 3-4. Sensory test 4]
In the same manner as Test Example 1-1, the compositions shown in Table 18 were prepared and used as test samples. Sensory evaluation was performed for each test sample. The test method is the same as Test Example 3-1. Figure 28 shows the results for "stimulation," Figure 29 shows the results for "hot flashes," Figure 30 shows the results for "tension," Figure 31 shows the results for "itch," and Figure 31 shows the results for "unnatural feeling." The results are shown in FIG. 32.

As shown in FIGS. 28 to 32, in Comparative Example 19 in which the ethanol content was 22.84% by weight or more, when applied to the back, 5 minutes after spraying, there was a feeling of irritation (FIG. 28), hot flashes ( The results showed that the patient felt tingling (Fig. 29), tingling (Fig. 30), itching (Fig. 31), and discomfort (Fig. 32). When Comparative Example 19 was applied to the arm, it was found that no irritation, hot flashes, tightness, itching, or discomfort were felt, indicating that the above-mentioned feeling of use was a problem unique to the back.

On the other hand, Example 3 containing component (A) and (B) less than 22.84% by weight of ethanol
9 and Example 40, 5 minutes after spraying, no irritation (Fig. 28), hot flashes (Fig. 29), tightness (Fig. 30), itching (Fig. 31), or discomfort (Fig. 32) were felt. The results were obtained.

[Test Example 3-5. Sensory test 5]
In the same manner as Test Example 1-1, the compositions shown in Table 19 were prepared and used as test samples. Sensory evaluation was performed for each test sample. The test method is the same as Test Example 3-1. Figure 33 shows the results for "stimulation," Figure 34 shows the results for "hot flashes," Figure 35 shows the results for "tension," Figure 36 shows the results for "itch," and Figure 36 shows the results for "unnatural feeling." The results are shown in FIG. 37.

As shown in FIGS. 33 to 37, in Comparative Example 20 in which the ethanol content was 22.84% by weight or more, when applied to the back, 5 minutes after spraying, there was a feeling of irritation (FIG. 33), hot flashes ( The results showed that the patient felt tingling (Fig. 34), tightness (Fig. 35), itching (Fig. 36), and discomfort (Fig. 37). When Comparative Example 20 was applied to the arm, no irritation, hot flashes, tightness, itching, or discomfort were felt, indicating that the above-mentioned feeling of use was a problem unique to the back.

On the other hand, Example 4 containing component (A) and less than 22.84% by weight of ethanol (B)
1 and Example 42, 5 minutes after spraying, no irritation (Figure 33), hot flashes (Figure 34), tightness (Figure 35), itching (Figure 36), or discomfort (Figure 37) were felt. The results were obtained.

[Test Example 3-6. Sensory test 6]
In the same manner as Test Example 1-1, the compositions shown in Table 20 were prepared and used as test samples. Sensory evaluation was performed for each test sample. The test method is the same as Test Example 3-1. Figure 38 shows the results for "stimulation," Figure 39 shows the results for "hot flashes," Figure 40 shows the results for "tension," Figure 41 shows the results for "itching," and Figure 41 shows the results for "unnatural feeling." The results are shown in FIG. 42.

As shown in FIGS. 38 to 42, in Comparative Example 21 in which the ethanol content was 22.84% by weight or more, when applied to the back, 5 minutes after spraying, there was a feeling of irritation (FIG. 38), hot flashes ( The results were that the patient felt tingling (Fig. 39), tingling (Fig. 40), itching (Fig. 41), and discomfort (Fig. 42). When Comparative Example 21 was applied to the arm, no irritation, hot flashes, tightness, itching, or discomfort were felt, indicating that the above-mentioned feeling of use was a problem unique to the back.

On the other hand, Example 4 containing component (A) and less than 22.84% by weight of ethanol (B)
3 and Example 44, 5 minutes after spraying, no irritation (Figure 38), hot flashes (Figure 39), tightness (Figure 40), itching (Figure 41), or discomfort (Figure 42) were felt. The results were obtained.

[Test Example 3-7. Sensory test 7]
In the same manner as in Test Example 1-1, the compositions shown in Table 21 were prepared and used as test samples. Sensory evaluation was performed for each test sample. The test method is the same as Test Example 3-1. Figure 43 shows the results for "stimulation," Figure 44 shows the results for "hot flashes," Figure 45 shows the results for "tension," Figure 46 shows the results for "itch," and Figure 46 shows the results for "uncomfortable feeling." The results are shown in FIG. 47.

As shown in FIGS. 43 to 47, in Comparative Example 22 in which the ethanol content was 22.84% by weight or more, when applied to the back, 5 minutes after spraying, there was a feeling of irritation (FIG. 43), hot flashes ( The results were that the patient felt tingling (Fig. 44), tingling (Fig. 45), itching (Fig. 46), and discomfort (Fig. 47). When Comparative Example 22 was applied to the arm, no irritation, hot flashes, tightness, itching, or discomfort were felt, indicating that the above-mentioned feeling of use was a problem unique to the back.

On the other hand, Example 4 containing component (A) and less than 22.84% by weight of ethanol (B)
Even with samples containing a small amount of POE (9) lauryl ether as a surfactant, as in Example 5 and Example 46, there was no irritation (Figure 43) or hot flashes (Figure 44) after 5 minutes of spraying.
The results showed that no particular sensation of tightness (Fig. 45), itchiness (Fig. 46), or discomfort (Fig. 47) was observed.

[Test Example 3-8. Sensory test 8]
In the same manner as Test Example 1-1, the compositions shown in Table 22 were prepared and used as test samples. Sensory evaluation was performed for each test sample. The test method is the same as Test Example 3-1. Figure 48 shows the results for "stimulation," Figure 49 shows the results for "hot flashes," Figure 50 shows the results for "tension," Figure 51 shows the results for "itch," and Figure 51 shows the results for "unnatural feeling." The results are shown in FIG. 52.

As shown in FIGS. 48 to 52, in Comparative Example 23 in which the ethanol content was 22.84% by weight or more, when applied to the back, 5 minutes after spraying, there was a feeling of irritation (FIG. 48), hot flashes ( The results were that the patient felt tingling (Fig. 49), tingling (Fig. 50), itching (Fig. 51), and discomfort (Fig. 52). When Comparative Example 23 was applied to the arm, no irritation, hot flashes, tightness, itching, or discomfort were felt, indicating that the above-mentioned feeling of use was a problem unique to the back.

On the other hand, Example 4 containing component (A) and less than 22.84% by weight of ethanol (B)
7 and Example 48, even samples that do not contain a surfactant show irritation (Figure 48), hot flashes (Figure 49), tightness (Figure 50), and itching (Figure 51) 5 minutes after spraying. ) and discomfort (FIG. 52) were not particularly felt.

In this way, Examples 33 to 48 improve the skin environment around acne by suppressing ``irritating feeling'', ``hot flashes'', ``tension'', ``itching'', and ``uncomfort'' more strongly than in areas other than the back. can be arranged. Therefore, the present invention can be more suitably used for acne occurring on the back compared to acne occurring on areas other than the back.

[Example of drug formulation]
Examples of formulations of the present invention are shown below. Solutions, creams, or ointments were prepared by conventional methods using the formulations shown in Tables 23 to 25. These preparations are effectively used for acne on the back. The liquid agent can also be used by being stored in a spray type container.

Claims (6)

(A) selected from the group consisting of salicylic acid and its salts, isopropylmethylphenol, sulfur, resorcinol, ibuprofenpiconol, dipotassium glycyrrhizinate, glycyrrhetinic acid, allantoin, zinc oxide, diphenhydramine, homosulfamine, sulfadiazine, and tocopherol acetate; at least one species, and
(B) A drug for preventing and/or treating acne for the back, containing less than 22.84% by weight of ethanol. The drug for preventing and/or treating acne for the back according to claim 1, wherein the total content of the component (A) is 0.0001% to 30% by weight. The drug for preventing and/or treating acne for the back according to claim 1 or 2, which is housed in a spray type container. The drug for preventing and/or treating acne on the back according to any one of claims 1 to 3, further comprising 1,3-butylene glycol and/or glycerin. The drug for preventing and/or treating acne for back according to any one of claims 1 to 4, which has a pH of 2.5 to 5.5. (A) selected from the group consisting of salicylic acid and its salts, isopropylmethylphenol, sulfur, resorcinol, ibuprofenpiconol, dipotassium glycyrrhizinate, glycyrrhetinic acid, allantoin, zinc oxide, diphenhydramine, homosulfamine, sulfadiazine, and tocopherol acetate; at least one species, and
(B) An external composition for inhibiting the growth of Malassezia fungi on the back, containing less than 22.84% by weight of ethanol.

Images